Acquired von Willebrand syndrome: Features and management

American Journal of Hematology

Volumn 81, Issue 8, 2006, Pages 616-623

  Mohri, Hiroshi ^a,b  

^a FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acquired von Willebrand syndrome; Diagnostic process; Inhibitor to vWF; Pathophysiology; Therapy

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CIPROFLOXACIN; COLLAGEN; DESMOPRESSIN; GRISEOFULVIN; HETASTARCH; IMMUNOGLOBULIN; PROTEIN PRECURSOR; RISTOCETIN; VALPROIC ACID; VON WILLEBRAND FACTOR;

ADSORPTION; BLEEDING TIME; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; HUMAN; IMMUNOPATHOLOGY; LYMPHOPROLIFERATIVE DISEASE; MYELOPROLIFERATIVE DISORDER; NEOPLASM; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SHEAR STRESS; THROMBOCYTE ACTIVATION; TUMOR CELL; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; VON WILLEBRAND DISEASE;

EID: 33746003275     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20455     Document Type: Review

References (81)

1. Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987;70:895-904.
2. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-525.
3. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Subcommittee on von Willebrand Factor. Thromb Haemost 2000;84:345-349.
4. Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91:3623-3629.
5. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31:806-812.
6. Stewart AK, Glynn MF. Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone. Postgrad Med J 1990;66:560-562.
7. Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand's disease. Transfusion 1985;27:234-237.
8. Friederich PW, Wever PC, Briet E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66:292-294.
9. Aylesworth CA, Smallridge RC, Rick ME, Alving BM. Acquired von Willebrand's disease: a rare manifestation of postpartum thyroiditis. Am J Hematol 1995;50:217-219.
10. Levesque H, Borg JY, Cailleux N, et al. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Eur J Med 1993; 2:287-288.
11. Takahashi H, Yamada M, Shibata A. Acquired von Willebrand's disease in hypothyroidism. Thromb Haemost 1987;58:1095.
12. Dalton RG, Dewar MS, Savidge GF, et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987;1: 1007-1009.
13. Van Genderen PJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80:495-498.
14. Casonato A, Pontara E, Doria A, et al. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. Br J Haematol 2002;116:899-904.
15. Mohri H, Hisanaga S, Mishima A, et al. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma; recognition sites present on the A1 loop and A3 domains of von Willebrand factor. Blood Coagul Fibrinolysis 1998;9:91-97.
16. Goudemand J, Samor B, Caron C, et al. Acquired type II von Willebrand's disease; demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment. Br J Haematol 1988;68:227-233.
17. van Genderen PJ, Vink T, Michiels JJ, et al. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand disease to collagen. Blood 1994; 84:3378-3384.
18. Scrobohaci ML, Daniel MT, Levy Y, et al. Expression of GPIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993;84:471-475.
19. Richard C, Cuadrado MA, Prieto M, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990;35:114-117.
20. Tefferi A, Hanson CA, Kurtin PJ, et al. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997;96:850-853.
21. Facon T, Caron C, Courtin P, et al. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. Br J Haematol 1992;80:488-494.
22. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Haemost 1997;23:425-431.
23. van Genderen PJ, Michiels JJ, van der Poel, et al. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol 1994;69:81-84.
24. van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocytopenia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997;99: 832-836.
25. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and hemorrhagic thrombocythemia. Presse Med 1994;23:73-77.
26. Gill JC, Wilson AD, Endres-Brooks J, Montgomery RR. Loss of the largest von Willebrand factor multimers from plasma of patients with congenital cardiac defects. Blood 1986;67:758-761.
27. Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet 1996;347: 689-690.
28. Strauss RG, Stump DC, Henriksen RA. Hydroxyethyl starch accentuates von Willebrand's disease. Transfusion 1987;25:235-237.
29. Mohri H. Acquired von Willebrand disease in patients with poly-cythemia rubra vera. Am J Hematol 1987;26:135-146.
30. Mohri H. Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia. Am J Hematol 1986;22: 391-401.
31. Pareti FI, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000;102:1290-1295.
32. Rodeghiero F, Castaman G, Lombardi R, Mannucci PM. Von Willebrand factor abnormalities in two patients with uraemia. Lancet 1988;2:1016-1017.
33. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: evidence for heightened proteolysis of von Willebrand factor. Am J Hematol 1995;49:83-86.
34. O'Brien JR, Etherington MD. Heart valve stenosis and von Willebrand's factor multimers. Lancet 1992;340:616.
35. Eikenboom JCJ, van der Meer FJM, Briet E. Acquired von Willebrand's disease due to excessive fibrinolysis. Br J Haematol 1992;81:618-620.
36. Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 2002;28:227-237.
37. Tefferi A, Nichols WL. Acquired von Willebrand disease: coccise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med 1997;103:536-540.
38. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand disease: a concise review. Am J Hematol 1997;54:139-145.
39. Federici AB, Stabile F, Castman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammo pathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92:2707-2711.
40. Mannucci PM, Lombardi R, Bader R, et al. Studies of the patho physiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 1984;64:614-621.
41. Mohri H, Tanabe J, Ohtsuka M, et al. Acquired von Willebrand disease associated with multiple myeloma; characterization of an inhibitor to von Willebrand factor. Blood Coagul Fibrinolysis 1995;6:561-566.
42. Mohri H, Noguchi T, Kodama F, et al. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987;87:663-668.
43. Bovill EG, Erschler WB, Golden EA, et al. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986;85: 115-123.
44. Gouault-Heilmann M, Dumont MD, Intrator L, et al. Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor. J Clin Pathol 1979;32:1030-1035.
45. Mazurier C, Parquet-Gernez A, Descamps J, et al. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Thromb Haemost 1980;19:115-119.
46. Wautier JL, Levy-Toledano ST, Caen JP. Acquired von Willebrand's syndrome and thrombopathy in a patient with chroniclymphocytic leukemia. Scand J Haematol 1976;16:128-134.
47. Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976;48:393-405.
48. Stewart MW, Etches WS, Shaw ARE, Gordon PA. VWf inhibitor detection by competitive ELISA. J Immunol Methods 1997; 200:113-119.
49. Mohri H, Yamazaki E, Suzuki Z, et al. Autoantibody selectively inhibits binding of vWF to GPIb. Recognition site is located in the A1 loop of vWF. Thromb Haemost 1997;77:760-766.
50. Duran-Saurez JR, Pico M, Zuazu J, et al. Acquired von Willebrand's disease caused by a chronic granulocytic leukemia. Br J Haematol 1981;48:173-175.
51. Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981-985.
52. Mohri H, Tanabe J, Yamazaki E, et al. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia. Hematopathol Mol Hematol 1996;10:123-133.
53. Budde U, Dent JA, Berkowitz SD, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981-985.
54. Fabris F, Casonato A, Del Ben MG, et al. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986;63:75-83.
55. Raman BK, Sawdyk M, Saeed SM. Essential thrombocythemia with acquired von Willebrand's disease. Am J Clin Pathol 1987; 88:102-106.
56. Coppes MJ, Zandvoort SWH, Sparling CR, et al. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol 1992; 10:422-427.
57. Scott JP, Montgomery RR, Tubergen DG, Hays T. Acquired von Willebrand's disease in association with Wilms' tumor: regression following treatment. Blood 1981;58:665-669.
58. Konety BR, Hord JD, Weiner ES, Schneck FX. Embryonal adenoma of the kidney associated with polycythemia and von Willebrand disease. J Urol 1998;160:2171-2174.
59. Sampson BM, Greaves M, Malia RG, Preston FE. Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases. Br J Haematol 1983;54:233-244.
60. Bruggers CS, McElligott K, Rallison ML. Acquired von Willebrand in twins with autoimmune hypothyroidism: response to desmopressin and 1-thyroxine therapy. J Pediatr 1994;125:911-913.
61. Viallard J, Pellegrin JL, Vergnes C, et al. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 1999;105:532-537.
62. Hanley D, Arkel YS, Lynch J, Kamiyama M. Acquired von Willebrand's syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin. Am J Hematol 1994;46:141-146.
63. Rauch R, Budde U, Koch A, et al. Acquired von Willebrand syndrome in children with patent ductus arteriosus. Heart 2002; 88:87-88.
64. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992;340:35-37.
65. Rosborough TK, Swaim WR. Acquired von Willebrand's disease, platelet-release defect and angiodysplasia. Am J Med 1978; 65:96-100.
66. Castman G, Rodeghiero F. Acquired transitory von Willebrand syndrome with ciprofloxacin. Lancet 1994;343:492.
67. Conrad ME, Latour LF. Acquired von Willebrand's disease, IgE polyclonal gammopathy, and griseofulvin therapy. Am J Hematol 1992;41:143.
68. Kreuz W, Linde R, Funk M, et al. Induction of von Willebrand disease type 1 by valproic acid. Lancet 1990;335:1350-1351.
69. Dalrymple-Hay M, Aitchison R. Collins R, et al. Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 1992;14:209-211.
70. Benson PJ, Peterson LC, Hasegawa DK, Smith CM. Abnormality of von Willebrand factor in patients with hemoglobin E-β thalas semia. Am J Clin Pathol 1990;93:395-399.
71. Zwaginga JJ, Ijsseldijk MJW, Beeser-Visser N, et al. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 1990;75:1498-1508.
72. Kinoshita S, Yoshioka K, Kasahara M. Takayama O. Acquired von Willebrand disease after Epstein-Barr virus infection. J Pediatr 1991;119:595-598.
73. Meyer D, Frommel D, Larrieu MJ, Zimmerman TS. Selective absence of large forms of factor VIII/von Willebrand factor in acquired von Willebrand's syndrome. Response to transfusion. Blood 1979;54:600-605.
74. Sampson B, Anderson BA, Schoen FJ. Acquired type 2A von Willebrand's disease: response to immunoglobulin infusion. Haemostasias 1998;27:286-289.
75. van Genderen PJ, Terpstra W, Michiels JJ, et al. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 1995;73:891-892.
76. Delmer A, Horellou MH, Brechot JM, et al. Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol 1992;40: 151-152.
77. van Genderen PJ, Michiels JJ, Bakker JJ, van't Veer MB. Effectiveness of high-dose intravenous gammaglobulin therapy in acquired von Willebrand's disease. Vox Sang 1994;87:14-17.
78. Arkel YS, Lynch J, Kamiyama M. Treatment of acquired von Willebrand's syndrome with intravenous immunoglobulin. Thromb Haemost 1994;72:643-644.
79. Gross S, Traulle C, Capiod JC, et al. Efficacy of high-dose intravenous gammaglobulin in the management of acquired von Willebrand's disease during orthopaedic surgery. Br J Haematol 1992;82:170-171.
80. White L, Chisholm M. Gastrointestinal bleeding in acquired von Willebrand's disease: efficacy of high-dose immunoglobulin where substitution treatment failed. Br J Haematol 1993;84: 332-334.
81. Frank RD, Kunz D, Wirtz DC. Acquired von Willebrand disease-hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion. Am J Hematol 2002;70:64-71.